Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Akio, Osa"'
Autor:
Kota Iwahori, Takuro Nii, Norihiko Yamaguchi, Takahiro Kawasaki, Satomi Okamura, Kazuki Hashimoto, Takanori Matsuki, Kazuyuki Tsujino, Keisuke Miki, Akio Osa, Sho Goya, Kinya Abe, Masahide Mori, Yoshito Takeda, Tomomi Yamada, Hiroshi Kida, Atsushi Kumanogoh
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Tetracyclines exhibit anti-viral, anti-inflammatory, and immunomodulatory activities via various mechanisms. The present study investigated the efficacy and safety of demeclocycline in patients hospitalized with mild-to-moderate COVID-19 via
Externí odkaz:
https://doaj.org/article/72a700e85525488189e0bb37c29e191b
Autor:
Kentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, Shohei Koyama, Yujiro Naito, Akio Osa, Takashi Hirai, Hidekazu Suzuki, Norio Okamoto, Takayuki Shiroyama, Kazumi Nishino, Yuichi Adachi, Takuro Nii, Yumi Kinugasa-Katayama, Akiko Kajihara, Takayoshi Morita, Seiya Imoto, Satoshi Uematsu, Takuma Irie, Daisuke Okuzaki, Taiki Aoshi, Yoshito Takeda, Toru Kumagai, Tomonori Hirashima, Atsushi Kumanogoh
Publikováno v:
JCI Insight, Vol 7, Iss 9 (2022)
Bronchoalveolar lavage is commonly performed to assess inflammation and identify responsible pathogens in lung diseases. Findings from bronchoalveolar lavage might be used to evaluate the immune profile of the lung tumor microenvironment (TME). To in
Externí odkaz:
https://doaj.org/article/641f4d15feef4e44af06979b1005ab6a
Autor:
Akio Osa, Takeshi Uenami, Yujiro Naito, Haruhiko Hirata, Shohei Koyama, Takayuki Takimoto, Takayuki Shiroyama, Shinji Futami, Saeko Nakatsubo, Nobuhiko Sawa, Yukihiro Yano, Izumi Nagatomo, Yoshito Takeda, Masahide Mori, Hiroshi Kida, Atsushi Kumanogoh
Publikováno v:
Thoracic Cancer, Vol 10, Iss 11, Pp 2183-2187 (2019)
Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients. Clinical trials usually exclude patients with renal dysfunction who are
Externí odkaz:
https://doaj.org/article/addd5ae67c1742ff8f10f548266ee3b5
Autor:
Yujiro Naito, Shohei Koyama, Kentaro Masuhiro, Takashi Hirai, Takeshi Uenami, Takako Inoue, Akio Osa, Hirotomo Machiyama, Go Watanabe, Nicolas Sax, Jordan Villa, Yumi Kinugasa-Katayama, Satoshi Nojima, Moto Yaga, Yuki Hosono, Daisuke Okuzaki, Shingo Satoh, Takeshi Tsuda, Yoshimitsu Nakanishi, Yasuhiko Suga, Takayoshi Morita, Kiyoharu Fukushima, Masayuki Nishide, Takayuki Shiroyama, Kotaro Miyake, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yukihiro Yano, Motohiro Tamiya, Toru Kumagai, Norihiko Takemoto, Hidenori Inohara, Sho Yamasaki, Kazuo Yamashita, Taiki Aoshi, Esra A. Akbay, Naoki Hosen, Yasushi Shintani, Hyota Takamatsu, Masahide Mori, Yoshito Takeda, Atsushi Kumanogoh
Publikováno v:
Science Advances. 9
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d75f8bfce4dc51fb9d93fdbbf6c1ab5
https://doi.org/10.1126/sciadv.ade0718
https://doi.org/10.1126/sciadv.ade0718
Autor:
Koji Azuma, Takashi Kusu, Akio Osa, Aiko Miyamoto, Norihiko Yamaguchi, Shunsuke Sakai, Kiyonori Nishioka, Kento Kuniya, Sho Goya, Kyo Hirayama
Publikováno v:
Haigan. 60:423-428
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bffabef92b3bfc33aefd2fdd5984e543
https://doi.org/10.2482/haigan.60.423
https://doi.org/10.2482/haigan.60.423
Autor:
Yu Futami, Akio Osa, Hyota Takamatsu, Kotaro Miyake, Yuki Hosono, Shingo Satoh, Izumi Nagatomo, Yuhei Kinehara, Satoshi Nojima, Yasuhiko Suga, Kiyoharu Fukushima, Atsushi Kumanogoh, Taro Koba, Haruhiko Hirata, Yujiro Naito, Yoshito Takeda, Shohei Koyama, Takeshi Nakatani, Takeshi Tsuda, Daisuke Okuzaki, Kota Iwahori, Daisuke Ito, Yoshimitsu Nakanishi, Masayuki Nishide, Takayuki Shiroyama
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 207(5)
Cancer immunotherapy has shown great promise as a new standard therapeutic strategy against cancer. However, the response rate and survival benefit remain unsatisfactory because most current approaches, such as the use of immune checkpoint inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95bd63b637e5c84b466062f92163fd5f
https://pubmed.ncbi.nlm.nih.gov/34380650
https://pubmed.ncbi.nlm.nih.gov/34380650
Publikováno v:
Journal of Visualized Experiments.
Immune checkpoint inhibitors, including PD-1-blocking antibodies, have significantly improved treatment outcomes in various types of cancer. The pharmacological efficacy of these immunotherapies is long lasting, extending even beyond the discontinuat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be446bd1c2dfa10ba89869525f8894a8
https://doi.org/10.3791/60608-v
https://doi.org/10.3791/60608-v
Publikováno v:
Internal Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e9d2784dcdb560c9d21fa872bac7f0
https://doi.org/10.2169/internalmedicine.3644-19
https://doi.org/10.2169/internalmedicine.3644-19
Autor:
Jie Meng, Akio Osa, Ryo Suzuki, Yasunari Haseda, Yasuo Yoshioka, Lisa Munakata, Shohei Koyama, Yoshiaki Okada, Kazuo Maruyama, Yoshihiko Tanimoto, Atsushi Kumanogoh, Taiki Aoshi, Yujiro Naito, Daiki Omata, Hirotomo Machiyama
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 313
Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via Toll-like receptor 9 (TLR9)-dependent signaling. However, the in vivo application
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcf84e1455fad60444fa2028134781f6
https://pubmed.ncbi.nlm.nih.gov/31629036
https://pubmed.ncbi.nlm.nih.gov/31629036
Autor:
Aya Tanaka, Shoko Sasaki, Hiroaki Azukizawa, Takeshi Nakatani, Akio Osa, Takashi Kijima, Takanori Matsuki, Tomoyuki Otsuka, Mikako Ishijima, Muneyoshi Kuroyama, Haruhiko Hirata
Publikováno v:
International Cancer Conference Journal. 6:38-41
We report a case of a 65-year-old woman with stage IV lung adenocarcinoma who experienced Stevens–Johnson syndrome (SJS) during afatinib therapy. The patient received afatinib as the first-line therapy after the confirmation of harboring an exon 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0763611d12215534a61a43ce2a0b09db
https://doi.org/10.1007/s13691-016-0269-3
https://doi.org/10.1007/s13691-016-0269-3